AbbVie Receives FDA Complete Response Letter for TrenibotulinumtoxinE

AbbVie announced that the FDA has issued a Complete Response Letter (CRL) for its Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE), an investigational botulinum toxin type E product intended for aesthetic use.¹ The agency’s feedback focused on manufacturing processes, with no cited concerns related to clinical safety or efficacy.

The company stated it is well positioned to address the FDA’s requests and intends to submit a response in the coming months, aiming to advance the regulatory review process without the need for additional clinical trials.

What did the FDA’s Complete Response Letter highlight?

According to AbbVie, the CRL centers exclusively on chemistry, manufacturing, and controls (CMC)-related aspects of the application. Importantly, the FDA did not request new clinical data or identify deficiencies in the safety or efficacy profile of TrenibotE.

This distinction is significant, as CMC-related issues—while potentially complex—are often considered more straightforward to resolve than clinical deficiencies. AbbVie expressed confidence in its ability to respond promptly, leveraging its established expertise in biologics manufacturing and neurotoxin development.

Roopal Thakkar, MD, executive vice president, research and development, and chief scientific officer at AbbVie, noted that despite the setback, the company remains confident in the strength of its submission and its ability to address the agency’s feedback efficiently.

Why is TrenibotE considered a novel neurotoxin?

TrenibotE represents a potential first-in-class botulinum neurotoxin serotype E. Unlike currently marketed serotype A toxins, which typically have a longer duration of action, TrenibotE is designed to deliver a rapid onset and shorter duration of effect.

Clinical data indicate that the product may begin showing effects as early as eight hours post-administration, with results lasting approximately two to three weeks. This profile could appeal to patients seeking more flexible or temporary aesthetic treatments, potentially expanding the use of neurotoxins in facial aesthetics.

The development program for TrenibotE included more than 2,100 patients across multiple studies, including two pivotal Phase 3 trials evaluating treatment for moderate-to-severe glabellar lines, as well as an open-label safety study.²

How could manufacturing challenges impact approval timelines?

Manufacturing-related CRLs can introduce delays depending on the scope of the requested information and any required process modifications. However, because no clinical issues were identified, AbbVie’s path forward may involve addressing documentation gaps, validating processes, or providing additional analytical data.

AbbVie indicated that it expects to resolve the FDA’s questions in a timely manner. A successful resubmission could allow the FDA to resume review without restarting the entire approval process.

What does this mean for the competitive aesthetics market?

If approved, TrenibotE could differentiate itself in the crowded botulinum toxin market by offering a shorter-acting alternative to existing treatments. This could open new use cases, such as trial treatments for first-time patients or applications where temporary effects are preferred.

AbbVie’s continued investment in aesthetic medicine aligns with broader industry trends toward personalized and flexible treatment options. While the

CRL introduces a temporary regulatory hurdle, the absence of clinical concerns may preserve confidence among clinicians and investors regarding the product’s potential.

Regulatory reviews for TrenibotE are also ongoing in international markets, where timelines and outcomes could further influence its global positioning.

References

1. AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. (2026 Apr 23). PR Newswire. https://prnmedia.prnewswire.com/news-releases/abbvie-provides-update-on-trenibotulinumtoxine-trenibote-biologics-license-application-in-the-us-302752132.html
2. Kuhns, L. (2026 Apr 1)Repeat TrenibotulinumtoxinE Treatment Is Effective, Safe for Glabellar Lines.. Dermatology Advisor. https://www.dermatologyadvisor.com/reports/repeat-trenibotulinumtoxin-e-treatment-effective-safe-glabellar-lines/